Alterola Biotech（ABTI）株式概要製薬会社であるアルテローラ・バイオテック社は、カンナビノイドおよびカンナビノイド様分子から製造される医薬品の開発に従事している。 詳細ABTI ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析株式の流動性は非常に低い 最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $8M )すべてのリスクチェックを見るABTI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0051該当なし内在価値ディスカウントEst. Revenue$PastFuture-7m12016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesAlterola Biotech, Inc. 競合他社cbdMDSymbol: NYSEAM:YCBDMarket cap: US$7.5mCNS PharmaceuticalsSymbol: NasdaqCM:CNSPMarket cap: US$6.7mSenesTechSymbol: NasdaqCM:SNESMarket cap: US$9.1mInMed PharmaceuticalsSymbol: NasdaqCM:INMMarket cap: US$6.8m価格と性能株価の高値、安値、推移の概要Alterola Biotech過去の株価現在の株価US$0.005152週高値US$0.2052週安値US$0.0002ベータ01ヶ月の変化0%3ヶ月変化2.00%1年変化n/a3年間の変化-86.82%5年間の変化n/aIPOからの変化-99.56%最新ニュースお知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).お知らせ • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.お知らせ • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元ABTIUS PharmaceuticalsUS 市場7D0%4.5%-4.1%1Yn/a37.3%20.6%株主還元を見る業界別リターン: ABTIがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: ABTI US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is ABTI's price volatile compared to industry and market?ABTI volatilityABTI Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.8%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.1%安定した株価: ABTIの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のABTIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aDewi Hitchcockalterola-abti.com/製薬会社であるアルテローラ・バイオテック社は、カンナビノイドおよびカンナビノイド様分子から製造される医薬品の開発に従事している。アルテローラ・バイオテック社は、カンナビノイドおよびカンナビノイド様分子から製造される医薬品の開発に従事しており、規制対象となるヒトおよび動物用医薬品、規制対象となる食品の開発、医薬品有効成分および食品用成分の製造、バイオアベイラビリティ、溶解性および安定性を向上させるための製剤化およびドラッグデリバリーに重点を置いている。アルテローラ・バイオテック社は英国バーケンヘッドに本社を置いている。もっと見るAlterola Biotech, Inc. 基礎のまとめAlterola Biotech の収益と売上を時価総額と比較するとどうか。ABTI 基礎統計学時価総額US$7.55m収益（TTM）-US$2.78m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率ABTI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ABTI 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$2.78m収益-US$2.78m直近の収益報告Sep 30, 2024次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%ABTI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 03:56終値2026/02/23 00:00収益2024/09/30年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alterola Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).
お知らせ • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.
お知らせ • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
